SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

NCT04408898 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Challenges with recruitment

Conditions

Head and Neck Cancer

Interventions

GENETIC: ADP-A2M4 in combination with pembrolizumab.

Sponsor

Adaptimmune